Skip to main content
Lucia López-Corral on Muck Rack

Lucia López-Corral

As seen in: Nature, Wiley Online Library, BMJ Open, MDPI, The Lancet
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Lucia

Contact Lucia, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Incidence, clinical risk factors, and biomarkers of SOS/VOD following allogeneic HSCT in adults. A real-life study by the Spanish group of HSCT and cell therapy (GETH-TC).

|
By Monica A. Cabrero, Mónica Rivera Cabrero, Juan Montoro, Miriam Sanchez-Escamilla, María Cuesta, Pedro Antonio González-Sierra, Lucia López-Corral, Jaime Sanz, Maria Pascual, María Jesús Pascual, José Luis Piñana, Arancha Bermúdez, José María BELLÓN, Guillermo Orti, Carlos Solano, Ariadna Pérez-Martínez, Valle Gómez-García de Soria, Karem Humala, Oriana López-Godino, Alejandro Luna de Abia, Silvia Filaferro, Pascual Balsalobre
| Nature Verified
Abstract Hepatic sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD) may occur after allo-HSCT. This retrospective study of 793 allo-HSCT performed in adult patients analyzes the impact of clinical risk factors and the EASIX score on the incidence and outcomes of SOS/VOD using Real-World data (GETH-TC registry). Severity and clinical risk factors were defined according to the EBMT-2023 criteria.
Open in Who Shared Issue with article?

Impact of fludarabine dosage on outcomes in large B-cell lymphoma patients treated with CAR T-cell therapy: a retrospective study of the CTIWP of the EBMT

|
By Guillaume Dachy, Ludovic Gabellier, Ibrahim Yakoub-Agha, Michael Daskalakis, Victoria Potter, Peter Dreger, Anne Huynh, Christof Scheid, Matthew Collin, Gabriel Brisou, Gerald G. Wulf, Rachel Protheroe, Carlos Solano Vercet, Lucia López-Corral, Peter Vandenberghe, Francis Ayuk, Stefania Bramanti, Jorinde D. Hoogenboom, Jürgen Kuball, Annalisa Ruggeri, Florent Malard, Jarl E. Mooyaart, Marjolein van der Poel
| Nature Verified
Abstract Lymphodepleting conditioning (LD) with fludarabine and cyclophosphamide is critical to ensure optimal expansion and persistence of CD19 CAR T-cells. We conducted a retrospective EBMT registry study to assess the impact of fludarabine dosing in LD on outcomes in large B-cell lymphoma (LBCL).
Open in Who Shared Issue with article?

Real-world experience of treosulfan in allogeneic stem cell transplantation in adult patients with myeloid malignancies. Spanish Group of SCT and Cell Therapy (GETH-TC) | Bone Marrow Transplantation

|
By Lucrecia Yáñez, María Salas, Guillermo Martín-Sánchez, Lucia López-Corral, Montserrat Rovira, M. Bermúdez, Juan Manuel Cerezo-Martín, Estefanía Pérez-López, Noemí Fernández-Escalada, Lucia España, Pascual Basalobre
| Nature Verified
Treosulfan, in combination with fludarabine, is currently approved in Europe and the USA as a preparative regimen for allo-HSCT in adult and pediatric patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It is viewed as a potential substitute for busulfan in conditioning regimens due to its enhanced toxicity profile and more consistent linear pharmacokinetics [1, 2].
Open in Who Shared Issue with article?
See all 12 articles